Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Louise Wilkie - Vice President-Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Mark McClung - Chief Operating Officer Jason Fontenot - Chief Scientific Officer Prathyusha Duraibabu - Chief Financial Officer Amy Pooler - Head of Research Conference Call Participants Reena Patel - RBC Capital M ...

Forward-Looking Statements Pioneering and Delivering the Future of Genomic Medicines This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to our focus on epigenetic regulation and delivery engineering, the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such ther ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30171 __ ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Louise Wilkie – Vice President-Investor Relations and Corporate Communications Sandy Macrae – Chief Executive Officer Nathalie Dubois-Stringfellow – Chief Development Officer Mark McClung – Chief Operating Officer Jason Fontenot – Chief Scientific Officer Prathyusha Duraibabu – Chief Financial Officer Lisa Rojkjaer – Chief Medical Officer Conference Call Participants Maury Raycroft – Jeff ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30171 _______ ...

Nav 1.7 Prion Undisclosed C9orf72 Huntington NEUROPATHIC PAIN PRION DISEASE NEUROLOGY ALS HUNTINGTON'S • Selectively repress expression of a mutant allele while allowing for the expression of the healthy allele 13 • Blocking Nav1.7 in the DRG is expected to prevent the transmission of nociceptive pain signals to the brain • Progressive, with no disease modifying therapy Fabry Disease (isaralgagene civaparvovec or ST-920) | --- | --- | --- | --- | |-------|-------|-------|------------------------------------ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30171 ______ ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2023 Earnings Conference Call April 27, 2023 8:30 AM ET Company Participants Louise Wilkie - VP, IR and Corporate Communications Alexander D. Macrae - President and CEO D. Mark McClung - EVP and COO Prathyusha Duraibabu - SVP, Principal Accounting Officer and CFO Jason D. Fontenot - SVP and Chief Scientific Officer Nathalie Dubois-Stringfellow - SVP and Chief Development Officer Bettina M. Cockroft - CMO Conference Call Participants Benjamin Burnett - Stifel Grego ...

Forward-Looking Statements Pioneering and Delivering the Future of Genomic Medicines This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to our focus on key strategic priorities, the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential t ...

Pioneering and Delivering the Future of Genomic Medicines Forward-Looking Statements 2 Four Clinical-Stage Programs Advancing Towards Potential Commercialization In-House Manufacturing Provides Flexibility and Control Sangamo in 2023: Value Thesis 1 2 Pioneer in CAR-Tregs • TX200 renal transplant Ph1/2 study progresses, with possible acceleration to prove biology and platform value. Second wave of potentially transformative autoimmune and neurology programs advancing into the clinic • Second of four wholly- ...